Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)

Immunotherapy is among the most rapidly evolving treatment strategies in oncology. The therapeutic potential of immune-checkpoint inhibitors is exemplified by the recent hail of Food and Drug Administration (FDA) approvals for their use in various malignancies. Continued efforts to enhance outcomes...

Descripción completa

Detalles Bibliográficos
Autores principales: Chae, Young Kwang, Arya, Ayush, Iams, Wade, Cruz, Marcelo R., Chandra, Sunandana, Choi, Jaehyuk, Giles, Francis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5956851/
https://www.ncbi.nlm.nih.gov/pubmed/29769148
http://dx.doi.org/10.1186/s40425-018-0349-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5956851/
https://www.ncbi.nlm.nih.gov/pubmed/29769148
http://dx.doi.org/10.1186/s40425-018-0349-3

Ejemplares similares